Effect of recombinant human brain natriuretic peptide combined with Shenfu injection in the treatment of acute myocardial infarction complicated with acute heart failure

Objective:To evaluate the efficacy and safety of the recombinant human brain natriuretic peptide (rhBNP) combined with Shenfu injection in treating acute myocardial infarction (AMI) complicated with acute heart failure (AHF).Methods:Sixty-two patients with AMI complicated with AHF were randomly divided into the rhBNP treatment group and rhBNP combined with Shenfu injection treatment group(combination group)(31 cases each group).The blood pressre,heart rate,24 hours urine output,dyspnea grade,plasma concentration of neuroendocrine hormone,ultrasonic cardiography parameters and incidence rate of adverse reaction between two groups before and after treatment were compared.Results:Compared with the rhBNP group,the differences of the diastolic pressure decreasing degree were not statistically significant(P>0.05),the 24 hours urine output increasing was obvious(P<0.01),the dyspnea improvement was significant(P<0.01),and the neuroendocrine hormone decreasing was obvious in combination group(P<0.01).After 6 months of treatment,the left ventricular ejection fraction significnatly increased(P<0.01),and the left ventricular end-diastolic dimension slightly decreased(P<0.05).Compared with the rhBNP group,the incidence rate of hypotension in combination group was lower(P<0.05).Under the SBP for 130 to 90 mmHg and DBP for 80 to 60 mmHg,no renal insufficiency or renal insufficiency aggravating in two groups was found.Conclusions:The rhBNP can effectively inhibit the activation of neuroendocrine hormone,and improve hemodynamics in patients with AMI complicated with AHF.The rhBNP combined with Shenfu injection can effectively improve the dyspnea,control heart failure,and promote the recovery left ventricular ejection fraction in patients with AMI complicated with AHF.